BaroSense, Inc., a Redwood City, CA-based medical device company specializing in the minimally invasive treatment of obesity, has received an undisclosed amount of funding as a part of the company’s Series B financing round from iNovia Capital, a Montreal-based manager of venture capital funds.
Commenting on the deal, Daniel Balbierz, President and CEO of BaroSense, said that this round should allow the company to complete U.S. clinical trials and obtain regulatory approval to commercialize its lead product.
FinSMEs
30/11/2009